Full Description
Improving the Therapeutic Ratio in Head and Neck Cancer provides a complete review of current approaches to modulating therapeutic sensitivity in head and neck cancer. It presents a broad background of current approaches and by highlighting the potential for clinical translational, introduces a roadmap for how to move promising preclinical findings into the clinic.
The book discusses topics such as immunotherapy and molecularly targeted therapies in head and neck cancer, PI3k/mTOR pathway, autophagy inhibition to sensitize HNC to radiation and chemotherapy, TAM and Eph/Ephrin family proteins and metabolic reprogramming to modulate therapeutic sensitivity. Additionally, it details approaches to improve the response to immunotherapy, and Chk1/2 inhibition in radiation and cetuximab resistance.
This book is a valuable source to head and neck cancer researchers and advanced students, and to those studying specific approaches in other model systems and disease sites.
Contents
1. Overview of head and neck cancer management2. The role of immunotherapy and molecularly targeted therapies in head and neck cancer3. Targeting the PI3K/mTOR pathway4. Autophagy inhibition to sensitize HNC to radiation and chemotherapy5. Overcoming head and neck cancer stem cells6. TAM Family proteins and therapy resistance7. Eph/Ephrin family proteins and theapy resistance8. Metabolic reprogramming to modulate therapeutic sensitivity9. FGFR and cMET10. Targeting GPCRs in HNC11. Improving the response to immunotherapy12. Chk1/2 inhibition in radiation and cetuximab resistance
